Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infectionsCAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership accelerating antibacterial products to address drug-resistant b ...

EL SEGUNDO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ: BYND) (the “Company” or “Beyond Meat”), a leader in plant-based meat, today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 0% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”) for a pro rata portion of (i) up to $202.5 million in aggregate principal amount of its new 7.00% Convertible Senior Secured Second Lien PIK Toggle Not ...

Core Viewpoint - Chicago Atlantic BDC, Inc. is set to release its financial results for the third quarter of 2025 on November 13, 2025, before the market opens, followed by a conference call at 9:00 a.m. Eastern Time [1][2]. Company Overview - Chicago Atlantic BDC, Inc. is a specialty finance company regulated as a business development company under the Investment Company Act of 1940, focusing on maximizing risk-adjusted returns on equity for stockholders [4]. - The company's investment strategy primarily involves direct loans to privately held middle-market companies, with a significant emphasis on the cannabis sector [4]. Conference Call Details - The conference call will be accessible to the general public, with a dial-in number provided for participants [2][5]. - A replay of the conference call will be available on the company's website by the end of the day on November 13, 2025 [3].

UASHAT, Canada, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Apuiat Wind Farm L.P., a 50-50 partnership between the Innu communities and Boralex Inc., is proud to announce that the Apuiat Wind Farm has reached commercial operation. The 200 MW facility is located on the Nitassinan (traditional territory) of the Uashat mak Mani-utenam First Nation. The wind project was initiated and co-developed by the Innu communities. It stands as their first national energy project and the first wind farm to be built in Québec’s Côte ...

CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its registered direct offering announced on October 21, 2025, for the purchase and sale of 1,750,000 common shares (the “Common Shares”) (or pre-funded warrants (the “Pre-Funded Warrants”) in lieu the ...

REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the Stifel 2025 Healthcare Conference, to be held to be held at the Lotte New York Palace Hotel, New-York, NY on November 11–13, 2025. Mr. London is sched ...

Core Insights - Lifecore Biomedical has signed an agreement to transfer commercial manufacturing of a leading injectable pharmaceutical product to its facilities, becoming the supplier of choice for this product after meeting regulatory requirements [1][2] - This marks the second agreement with the same multinational organization in recent months, indicating Lifecore's growing reputation for quality and reliability in sterile injectables [1][2] - Additionally, Lifecore has entered into a pre-clinical formulation development agreement with an early-stage biotech company, further expanding its early-stage program pipeline [2] Company Strategy - The commercial site transfer is part of Lifecore's growth strategy to expand its CDMO business and build long-term partnerships with leading global pharmaceutical companies [2] - The new agreement will broaden Lifecore's commercial customer base and increase capacity utilization while allowing entry into new modalities [2] - Lifecore aims to capitalize on strong industry momentum and strengthen its position as a trusted U.S.-based CDMO partner [3] Company Background - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of expertise and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [4]

TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to provide an update on the ongoing drilling program at the Company’s Mercur Gold Project (“Mercur”) in Utah and the Beartrack-Arnett Gold Project (“Beartrack-Arnett”) in Idaho. Highlights Mobilized a new core rig to Beartrack-Arnett bringing the total number of rigs drilling on the Company’s projects to four.At Mercur, received assay results from 16 additional drill holes with ...

Coincides with Release of ACM Shanghai Third Quarter 2025 ResultsFREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, today announces expectations for preliminary unaudited revenue and total shipments for the third quarter of 2025. Today’s release coincides with the as-scheduled release of unaudited financial results by ACM Research (Shanghai), Inc., ACM’ ...

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using ...